18th Annual Symposium on Anti-Angiogenesis and Immune Therapies for Cancer

Through didactic presentations, interactive panel discussions, and QandA sessions, the 2.5 day conference will serve as a platform to discuss and evaluate many of the clinical challenges for optimal integration of anti-angiogenesis and immune-modulating agents into existing treatment paradigms for cancer care, appropriate selection of patients based on biomarker profiles for individualized treatment strategies, and use of these agents in the adjuvant and advanced disease settings.

Featuring presentations from more than 25 investigators, sessions will include:

1. Basic Science: Update on Angiogenesis
2. Basic Science: Update on Tumor Immunology
3. Crosstalk in Tumor Immunology and Preclinical Modeling
4. Novel Approaches to Activate the Immune Response to Tumor Antigens
5. Controversies with New Therapeutics Targeting Angiogenesis and Tumor Immunology
6. Biomarkers and Predictors of Response
7. Overview of Clinical Trials of AgentsTargeting Angiogenesis and Tumor Immunology: Clinical Trial Overview

Focusing on both clinical and basic research, topics will focus on cutting edge science in the field, highlighting novel strategies under both pre-clinical and clinical development. They encourage clinicians, scientists, and other healthcare professionals who work in the area of tumor immunology to attend.

Price:
Early - Physician, Pharmacist and PhD (expires Dec 3): USD 275.00
Discounted - Physician, Pharmacist and PhD (expires Jan 21): USD 300.00
Regular - Physician, Pharmacist and PhD (paid after Jan 21): USD 325.00
Pharmaceutical Industry Staff Members*: USD 400.00
Early - Nurses/Students/ Fellows/Trainees (expires Dec 3): USD 100.00
Early - Nurses/Students/ Fellows/Trainees (expires Jan 21): USD 125.00
Regular - Nurses/Students/ Fellows/Trainees (paid after Jan 21): USD 150.00.

Speakers:
Dr. Lee M. Ellis, Dr. Rober Kerbel, Dr. Helen Chen, Dr. George W. Sledge, Dr. Mario Sznol, Dr. Axel Grothey.